Serious and Progressive Neuropathy Presumably Post-Shingrix Vaccination

We present a case of serious and progressive neuropathy shortly following the administration of the herpes zoster subunit (HZ/su) vaccine, otherwise known as Shingrix. The progressive neuropathy occurred a week following the vaccination and progressed until discharge 16 days post-admittance. The pat...

Full description

Bibliographic Details
Main Authors: Michael J. Wons, Avani Vaghela, Amna Khalid, Benjamin D. Brooks
Format: Article
Language:English
Published: MDPI AG 2024-01-01
Series:Reports
Subjects:
Online Access:https://www.mdpi.com/2571-841X/7/1/5
Description
Summary:We present a case of serious and progressive neuropathy shortly following the administration of the herpes zoster subunit (HZ/su) vaccine, otherwise known as Shingrix. The progressive neuropathy occurred a week following the vaccination and progressed until discharge 16 days post-admittance. The patient’s mild symptoms persist. The development of neuropathy following HZ/su administration is exceedingly rare, with an attributable risk of three cases per million vaccines administered. A black box warning was issued for this indication, although diagnosis and treatment were not confirmed for this patient. Reporting cases like this is crucial for a comprehensive understanding of vaccine risks and to characterize the underlying etiology of these serious adverse events.
ISSN:2571-841X